SOSAFE
24.5.2024 10:41:26 CEST | Business Wire | Press release
SoSafe, Europe’s largest security awareness and human risk management vendor, has announced the launch of their pioneering Human Risk Operating System, The Human Risk OS™, a set of capabilities designed to help customers identify, quantify, monitor, and intervene on human security risk. SoSafe has also presented new capabilities to its Sofie Human Security Copilot, an AI-powered multi-channel agent built entirely on advanced Large Language Models, as well as incremental updates to its flagship product offering such as next-level personalized learning, behavioral phishing simulation, novel security operations and 3rd party data integrations. With that, SoSafe is leading the category evolution from security awareness to human risk management in response to escalating cyber threats and the need for security strategies to address human risk more holistically.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240524947770/en/
SoSafe launches The Human Risk OS™, bringing together all of SoSafe’s security offerings into a single cohesive platform that helps security teams to drive a holistic human risk management strategy and foster security cultures. Copyright: SoSafe GmbH
Dr Niklas Hellemann, Psychologist and CEO at SoSafe: “To achieve real risk reduction and meet the demands of security leaders, basic awareness measures alone don’t cut it. While traditional and generic awareness programs focus on awareness and knowledge transfer–educating individuals about potential threats and instructing them on response strategies–this approach often falls short in today’s dynamic environment. The evolving landscape requires an evolution to holistic human risk management, which prioritizes the outcomes and the drivers of behavior and helps to sustainably mitigate human risks.”
The Human Risk OS™ brings together all of SoSafe’s security offerings into a single cohesive platform that helps security teams to drive a holistic human risk management strategy and foster security cultures. It focuses on proactively managing security risks through real-time risk detection and continuous analyses, provides enhanced behavioural insights and recommends targeted interventions to customize and optimize defensive responses.
Its three core elements are:
- Human Behavior Sensors measure an organization’s digital activities, behaviors, and security culture, creating individual and group-level profiles of security behavior.
- The Human Security Index processes this tracked data and additional contextual information such as level of seniority, tenure, digital access, and functional criticality to create a single index that summarizes security performance for groups and organizations. This score allows organizations to quickly identify concern areas, track progress, and evolution over time, and the impact of different possible interventions.
- The Intervention Hub suggests intervention strategies to mitigate human-related security risks and drive behavioral change and healthy security.
Gonçalo Gaiolas, CPO at SoSafe: “We believe in the power of people in the fight against cybercrime. With The Human Risk OS™, organizations invest in more than just a security solution—they invest in a proactive approach to mitigating human-centric risk and securing their organization's future by putting people at the very center of their efforts. We empower organizations to drive behavioral change and build security cultures by identifying, quantifying, actively managing, and reducing their human risk and by focusing on efficiency to relieve the pressure on overstretched security teams.”
SoSafe also introduced additional capabilities to its “Sofie Human Security Copilot”, an AI-powered multi-channel agent built to meaningfully reduce human risk. Sofie supports security professionals and users with rapid threat awareness, situational awareness, and zero-level security and compliance support. Security leaders can now incorporate organisational policies and specifics into their responses. Built on advanced large language models and featuring an engaging interface, Sofie provides answers to support questions at any time, sends urgent security alerts, and educates users on security best practices, all customized to specific organizational needs and policies.
Unlike other conversational AI-solutions, Sofie focuses on making each interaction with the end user a learning moment in their daily work environment, not just delivering informative content, but also aiming to change behavior.
Gonçalo Gaiolas: “Cybercriminals are already harnessing the power of AI to enhance their social engineering attacks. It's time to use the full potential of AI on the defensive side as well. Our AI-powered multi-channel agent ‘Sofie’ demonstrates the power of AI for cyber defenses: It’s a multifunctional tool that makes security information accessible to everyone anytime, provides learning opportunities in every interaction, and supports security administrators with content and communication, automating responses to free up their team’s capacity. ‘Sofie’ makes cybersecurity part of our everyday work, manifesting security cultures as the most essential part of holistic human risk management.”
Ilona Simpson, longstanding CIO and Executive Advisor at SoSafe: “SoSafe’s Human Risk OS™ and Sofie help security leaders to efficiently drive a human risk management strategy that sustainably mitigates risk. Based on behavioral data and fueled with new technology, SoSafe simplifies where others complicate, making it easy for security professionals to strengthen the human layer as the most versatile part of our defense strategy. SoSafe's focus on automation and efficiency not only saves security teams significant time but also amplifies their results, enhancing overall security posture.”
SoSafe presented its product innovations “The Human Risk OS™” and “Sofie Human Security Copilot” with its new capabilities during a launch event on May 23rd in Cologne, Germany and via livestream in front of more than 300 industry guests.
About SoSafe
SoSafe, founded by a team of behavioral scientists and technology experts, is the largest security awareness and human risk management vendor based in Europe. SoSafe is empowering over 4700 customers worldwide to effectively mitigate cyber risk. With a unique human-centric approach grounded in behavioral science, SoSafe enhances secure behavior across organizations, making it intuitive and second nature. The platform is designed to strengthen digital self-defense by creating robust security cultures that actively involve employees in mitigating human risks. By leveraging psychology and advanced technology and AI, it enables security professionals to effectively identify, prioritize, manage, and ultimately reduce their human risk. The SoSafe team now consists of more than 450 employees in seven locations: Cologne (headquarters), Amsterdam, Berlin, London, Paris, Lisbon, and Munich.
Website: www.sosafe-awareness.com/
LinkedIn: www.linkedin.com/company/sosafe-cyber-security/mycompany/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240524947770/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
